Videos

Predicting T-cell toxicity is a key factor when it comes to successfully using CAR T-cell therapy, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.

Ulka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Bone marrow derived cancer-associated fibroblasts promote tumor progression which can alter a treatment's course, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.

Praveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Albert J. Aboulafia, MD, discusses targeted therapy options in tenosynovial giant cell tumor.

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Praveen Ramakrishnan, MD, discusses the benefit of CAR T-cell therapy in patients with mantle cell lymphoma.

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.

The medical director of the Comprehensive Stroke Center at Cleveland Clinic detailed the differences between neuroprotection and neurorestoration, and the available options for each.

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discusses his early stage gene therapy trial for Dravet syndrome.

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.